|
Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial
RECRUITINGPhase 1Sponsored by Juan Luis Vásquez
Actively Recruiting
PhasePhase 1
SponsorJuan Luis Vásquez
Started2026-10-12
Est. completion2030-04-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07555769
Summary
This phase I study evaluates intravesical calcium electroporation (CaEP) with a new transurethral electrode. The study is primarily designed to assess the safety of CaEP and secondarily, to preliminary explore the efficacy in patients with limited alternative therapies. The anticipated benefits and structured safety precautions justify the ethical conduct of the investigation.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Age ≥ 18 years and able to understand participant information and give informed consent * Histologically verified urothelial bladder tumor * Unfit for cystectomy and/or radiotherapy * Patients with recurrence after radiotherapy unfit for salvage cystectomy * Disease where other treatments are considered unsuitable or have been declined by the patient * The patient may receive simultaneous systemic treatment * Selected high-burden non-muscle-invasive bladder tumors after MDT assessment * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2 * Life expectancy of ≥ 3 months * Patients must be deemed able to tolerate general anesthesia * Sexually active participants in the reproductive age must use contraception. Accepted contraception includes the use of intrauterine device (IUD), oral contraceptives, male or female condom, vasectomy or female sterilization * Patients must stop treatment with anticoagulants before surgery in accordance with national guidelines * Plasma ionized Ca2+ must be within the normal upper limit. Correction is allowed * Hematology * Thrombocytes ≥ 50 billion/L * International normalized ratio (INR) ≤ 1.5. Correction is allowed Exclusion Criteria: * Pregnancy (confirmed by a blood sample) or lactation * Allergy to calcium gluconate or any of its excipients * Any clinical condition or previous treatment, that in the investigators' opinion made the patient ineligible * Contraindications to treatment with calcium gluconate as described: * Hypersensitivity to calcium gluconate or any of its excipients * Hypercalcemia (e.g. due to hyperparathyroidism, hypervitaminosis D, decalcifying malignancies, renal insufficiency, immobilization osteoporosis, sarcoidosis, milk-alkali syndrome)
Conditions5
Bladder TumorBladder TumorsCancerUrothelial Carcinoma (UC)Urothelial Carcinoma Bladder
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1
SponsorJuan Luis Vásquez
Started2026-10-12
Est. completion2030-04-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07555769